Grundlæggende statistik
| CIK | 1618561 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nexvet Biopharma plc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| February 13, 2018 |
NVET / Nexvet Biopharma plc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2017 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36828 Nexvet Biopharma public limited company (Exact name of regi |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| July 31, 2017 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2017 Registration No. |
|
| July 31, 2017 |
Nexvet Biopharma plc Unit 5, Sragh Technology Park Rahan Road, Tullamore Co. Offaly, R35 FR98, Ireland By EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Nexvet Biopharma public limited company Registration Statement on Form S-3 (File No. 333-210876) Ladies and Gentlemen: Nexvet Biopharma public limited company (the ? |
|
| July 31, 2017 |
EX-99.9 Exhibit 99.9 Nexvet Biopharma plc (Nexvet) Rule 17(d) Announcement DUBLIN, Ireland, July 28, 2017 (GLOBE NEWSWIRE) Nexvet Biopharma (Nasdaq:NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PLC to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 o |
|
| July 31, 2017 |
EX-99.3 Exhibit 99.3 The Directors Nexvet Biopharma Public Limited Company (the ?Company?) Unit 5 Sragh Business Park Rahan Road Tullamore County Offaly Dear Sirs I, Ashraf Elfar Hanna of 25 Sunrise Ct., Menlo Park, California, 94025, United States, hereby resign as a director of the Company with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circular) |
|
| July 31, 2017 |
EX-99.8 Exhibit 99.8 The Directors Nexvet Biopharma Public Limited Company (the ?Company?) Unit 5 Sragh Business Park Rahan Road Tullamore County Offaly Dear Sirs I, John Payne of 9900 NE, 114th Circle, Vancouver, WA 98662, United States, hereby resign as a director of the Company with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circular) dated 2 Jun |
|
| July 31, 2017 |
EX-99.1 Exhibit 99.1 The Directors Nexvet Biopharma Public Limited Company Nexvet Australia Pty Ltd Nexvet US Inc Nexvet Ireland Limited NVIP Pty Ltd Tevxen Limited (together, the ?Companies?) Dear Sirs I, Christopher Brown of 330A Canterbury Road, St. Kilda West, Victoria 3182, Australia, hereby resign as a director of the Companies with effect from the Effective Time (as defined in the proxy sta |
|
| July 31, 2017 |
EX-99.5 Exhibit 99.5 The Directors Nexvet Biopharma Public Limited Company BioNua Limited Nexvet Ireland Limited Tevxen Limited (together the ?Companies?) Dear Sirs I, Cormac Kilty of 34 Dundela Park, Sandycove, County Dublin, Ireland, hereby resign as a director of the Companies with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circular) dated 2 June |
|
| July 31, 2017 |
EX-99.2 Exhibit 99.2 The Directors Nexvet Biopharma Public Limited Company (the ?Company?) Unit 5 Sragh Business Park Rahan Road Tullamore County Offaly Dear Sirs I, George William Gunn of Gottardstrasse 4, 6490 Andermatt, Uri, Switzerland, hereby resign as a director of the Company with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circular) dated 2 J |
|
| July 31, 2017 |
EX-99.4 Exhibit 99.4 The Directors Nexvet Biopharma Public Limited Company (the ?Parent?) Nexvet Australia Pty Ltd Nexvet US Inc BioNua Limited Nexvet Ireland Limited NVIP Pty Ltd Tevxen Limited (together, the ?Companies?) Dear Sirs I, Mark Heffernan of 1A Gwynne Street, Hamlyn Heights, Victoria 3215, Australia, hereby resign as a director of the Companies with effect from the Effective Time (as d |
|
| July 31, 2017 |
Zoetis Completes Acquisition of Nexvet Biopharma EX-99.10 Exhibit 99.10 FOR IMMEDIATE RELEASE: July 31, 2017 Zoetis Media Contacts: Zoetis Investor Contact: Elinore White Steve Frank 1-973-443-2835 (o) 1-973-822-7141 (o) [email protected] [email protected] Bill Price 1-973-443-2742 (o) [email protected] Nexvet Media Contact: Nexvet Investor Contact: Damian Lismore Hershel Berry CFO, Nexvet Biopharma plc Blueprint Life Scienc |
|
| July 31, 2017 |
EX-99.7 Exhibit 99.7 The Directors Nexvet Biopharma Public Limited Company (the ?Company?) Unit 5 Sragh Business Park Rahan Road Tullamore County Offaly Dear Sirs I, Rajiv Patel of 2360 Washington Street, San Francisco, California 94115, United States, hereby resign as a director of the Company with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circula |
|
| July 31, 2017 |
EX-99.6 Exhibit 99.6 The Directors Nexvet Biopharma Public Limited Company (the ?Company?) Unit 5 Sragh Business Park Rahan Road Tullamore County Offaly Dear Sirs I, Joseph McCracken of 632 Fairway Circle, Hillsborough, California, 94010, United States, hereby resign as a director of the Company with effect from the Effective Time (as defined in the proxy statement (incorporating the scheme circul |
|
| July 31, 2017 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incor |
|
| July 10, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 10, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| July 10, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 17(c) Announcement EX-99.2 Exhibit 99.2 Nexvet Biopharma plc (?Nexvet?) Rule 17(c) Announcement DUBLIN, Ireland ? July 10, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PLC to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Com |
|
| July 10, 2017 |
EX-99.1 Exhibit 99.1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (as amended by special resolution passed on 10 July 2017) 1 The name of the Company is: Nexvet Biopharma public limited company. 2 The Company i |
|
| July 5, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? July 5, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on July 3, 2017 its issued share capital comprised 12,144,941 ord |
|
| July 5, 2017 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 5, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| July 5, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? July 5, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on July 3, 2017 its issued share capital comprised 12,144,941 ord |
|
| July 5, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 5, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| June 30, 2017 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| June 19, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 19, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on June 16, 2017 its issued share capital comprised 11,922,150 o |
|
| June 19, 2017 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 19, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| June 19, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 19, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on June 16, 2017 its issued share capital comprised 11,922,150 o |
|
| June 19, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 19, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| June 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 16, 2017 |
EX-99.2 Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the action you should take, you should consult an independent financial adviser who, if you are taking advice in Ireland, is authorized or exempted under the European Communities (Markets in Financial Instruments) Regulations 2007 (S.I. No. 60 of 2007) (as amended) or the Investment |
|
| June 16, 2017 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| June 16, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 15 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 15 Announcement DUBLIN, Ireland ? June 16, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 |
|
| June 16, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| June 16, 2017 |
EX-99.2 Exhibit 99.2 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the action you should take, you should consult an independent financial adviser who, if you are taking advice in Ireland, is authorized or exempted under the European Communities (Markets in Financial Instruments) Regulations 2007 (S.I. No. 60 of 2007) (as amended) or the Investment |
|
| June 16, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 15 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 15 Announcement DUBLIN, Ireland ? June 16, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 |
|
| June 14, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 14, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on June 13, 2017 its issued share capital comprised 11,922,150 o |
|
| June 14, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incor |
|
| June 14, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 14, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incor |
|
| June 14, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 14, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on June 13, 2017 its issued share capital comprised 11,922,150 o |
|
| June 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 13, 2017 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Nexvet Biopharma plc File No. |
|
| June 7, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 17(b) Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 17(b) Announcement DUBLIN, Ireland ? June 6, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part |
|
| June 7, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| June 7, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 17(b) Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 17(b) Announcement DUBLIN, Ireland ? June 6, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part |
|
| June 7, 2017 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| June 5, 2017 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro |
|
| June 2, 2017 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 2, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 17 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 17 Announcement DUBLIN, Ireland ? June 2, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 o |
|
| June 2, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| June 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporation) |
|
| June 2, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 17 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 17 Announcement DUBLIN, Ireland ? June 2, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following; Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement under Chapter 1 of Part 9 o |
|
| June 2, 2017 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| June 2, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 1, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following. In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on May 31, 2017 its issued share capital comprised 11,919,879 ord |
|
| June 2, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? June 1, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced the following. In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on May 31, 2017 its issued share capital comprised 11,919,879 ord |
|
| June 2, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| May 12, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 d384310d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisd |
|
| May 12, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? May 11, 2017- Nexvet Biopharma (Nasdaq: NVET) today announced the following. In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on May 10, 2017 its issued share capital comprised 11,916,712 ordi |
|
| May 12, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| May 12, 2017 |
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement EX-99.1 Exhibit 99.1 Nexvet Biopharma plc (?Nexvet?) Rule 2.10 Announcement DUBLIN, Ireland ? May 11, 2017- Nexvet Biopharma (Nasdaq: NVET) today announced the following. In accordance with Rule 2.10 of the Irish Takeover Panel Act 1997, Takeover Rules, 2013 (the ?Irish Takeover Rules?), Nexvet confirms that as at close of business on May 10, 2017 its issued share capital comprised 11,916,712 ordi |
|
| May 11, 2017 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2017 |
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017 DUBLIN, Ireland ? May 11, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three and nine month periods ended March 31, 2017. Recent highlights: ? In April 2017, entered into a Transaction Agreement for Zoetis to acquire all Nexvet shares for $6.72 per ordinary share in c |
|
| May 11, 2017 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| May 11, 2017 |
NVET / Nexvet Biopharma plc 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36828 Nexvet Biopharma p |
|
| May 11, 2017 |
Non-Exclusive Patent License Agreement by and between Nexvet Ireland Limited and Pfizer Inc. Pfizer-Nexvet CONFIDENTIAL EXECUTION COPY Exhibit 10.1 NON-EXCLUSIVE PATENT LICENSE AGREEMENT by and between PFIZER INC. and NEXVET IRELAND LIMITED Dated as of February 1, 2017 Pfizer-Nexvet CONFIDENTIAL NON-EXCLUSIVE PATENT LICENSE AGREEMENT This Non-Exclusive Patent License Agreement (the “Agreement”) is made as of February 1, 2017 (the “Effective Date”) by and between Pfizer Inc. a corporation |
|
| May 11, 2017 |
Statement Regarding Computation of Ratio of Earnings to Fixed Charges and Preference Share Dividends Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) Three Months Ended Nine Months Ended March 31, March 31, 2017 2016 2017 2016 Earnings: Net loss $ (6,019 ) $ (5,745 ) $ (16,526 ) $ (15,396 ) Add: Fixed charges 26 26 77 61 Earnings as defined $ (5,993 ) $ (5,719 ) $ (16,449 ) $ (15,335 ) Fixed charges: Estimated interes |
|
| April 19, 2017 |
NVET / Nexvet Biopharma plc / FARALLON CAPITAL MANAGEMENT LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2017 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 13, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorpora |
|
| April 18, 2017 |
COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION EX-99.1 Exhibit 99.1 Zoetis to Acquire Nexvet for US$6.72 in Cash Per Share PARSIPPANY, N.J. & TULLAMORE, Ireland(BUSINESS WIRE) COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATION |
|
| April 18, 2017 |
EX-10.1 Exhibit 10.1 DATED APRIL 13, 2017 ZOETIS INC AND NEXVET BIOPHARMA LIMITED EXPENSES REIMBURSEMENT AGREEMENT CONTENTS 1. INTERPRETATION 1 2. PRE-CONDITION 7 3. ZOETIS REIMBURSEMENT 7 4. GENERAL 10 THIS AGREEMENT is made as a deed on April 13, 2017 BETWEEN: (1) ZOETIS INC., a Delaware corporation, with a principal place of business at 10 Sylvan Way, Parsippany, New Jersey 07054 (?Zoetis?), an |
|
| April 18, 2017 |
EX-2.1 Exhibit 2.1 DATED APRIL 13, 2017 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY ZOETIS INC. ZOETIS BELGIUM S.A., TRANSACTION AGREEMENT CONTENTS 1. Interpretation 1 2. Rule 2.5 Announcement and Scheme Document 14 3. Implementation of the Scheme 15 4. Rule 15 Proposals 24 5. Target and Zoetis Conduct 26 6. Warranties 30 7. Additional Agreements 51 8. Completion of Acquisition 58 9. Termination 59 10 |
|
| April 18, 2017 |
EX-10.1 Exhibit 10.1 DATED APRIL 13, 2017 ZOETIS INC AND NEXVET BIOPHARMA LIMITED EXPENSES REIMBURSEMENT AGREEMENT CONTENTS 1. INTERPRETATION 1 2. PRE-CONDITION 7 3. ZOETIS REIMBURSEMENT 7 4. GENERAL 10 THIS AGREEMENT is made as a deed on April 13, 2017 BETWEEN: (1) ZOETIS INC., a Delaware corporation, with a principal place of business at 10 Sylvan Way, Parsippany, New Jersey 07054 (?Zoetis?), an |
|
| April 18, 2017 |
EX-2.1 Exhibit 2.1 DATED APRIL 13, 2017 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY ZOETIS INC. ZOETIS BELGIUM S.A., TRANSACTION AGREEMENT CONTENTS 1. Interpretation 1 2. Rule 2.5 Announcement and Scheme Document 14 3. Implementation of the Scheme 15 4. Rule 15 Proposals 24 5. Target and Zoetis Conduct 26 6. Warranties 30 7. Additional Agreements 51 8. Completion of Acquisition 58 9. Termination 59 10 |
|
| April 18, 2017 |
COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION EX-99.1 Exhibit 99.1 Zoetis to Acquire Nexvet for US$6.72 in Cash Per Share PARSIPPANY, N.J. & TULLAMORE, Ireland?(BUSINESS WIRE)? COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATION |
|
| April 18, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 13, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorpora |
|
| March 13, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorpora |
|
| March 13, 2017 |
Deed of separation Date 10 March 2017 EX-10.1 2 d256844dex101.htm EX-10.1 Exhibit 10.1 Deed of separation Nexvet Australia Pty Ltd ACN 141 909 131 and Nexvet Biopharma plc Company No. 547923 and David Gearing Table of contents 1. Definitions and interpretation 3 2. Termination of employment 5 3. Benefits 5 4. Acknowledgements 6 5. Releases 6 6. Confidentiality and intellectual property 7 7. Warranties and indemnities 7 8. General 8 Sc |
|
| February 14, 2017 |
NVET / Nexvet Biopharma plc / Foresite Capital Fund II, L.P. - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* NexVet Biopharma PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2016 (Date of Event Which Require |
|
| February 10, 2017 |
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 DUBLIN, Ireland ? February 10, 2017 ? Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three and six month periods ended December 31, 2016. Recent highlights: ? Initiated pivotal field efficacy and safety studies of frunevetmab, the Company?s anti-nerve growth factor monoclonal |
|
| February 10, 2017 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 10, 2017 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of I |
|
| February 10, 2017 |
Nexvet Biopharma 10-Q (Quarterly Report) nvet-10q20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 10, 2017 |
Nexvet Biopharma 3G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2017 |
Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) December 31, December 31, 2016 2015 2016 2015 Earnings: Net loss $ (5,412 ) $ (5,691 ) $ (10,507 ) $ (9,651 ) Add: Fixed charges 35 29 51 35 Earnings as defined $ (5,377 ) $ (5,662 ) $ (10,456 ) $ (9,616 ) Fixed charges: Estimated interest component of rental expense (1) |
|
| February 9, 2017 |
NVET / Nexvet Biopharma plc / Adage Capital Partners GP LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEXVET BIOPHARMA PLC (Name of Issuer) Ordinary Shares, $0.0125 nominal value per share (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| January 11, 2017 |
NVET / Nexvet Biopharma plc / AustralianSuper Pty Ltd - NEXVET13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Nexvet Biopharma public limited company (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) June 22, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| November 18, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 17, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| November 4, 2016 |
Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017 DUBLIN, Ireland ? November 4, 2016 ? Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three month period ended September 30, 2016. Recent highlights include: ? Advanced preparations for pivotal studies of the anti-NGF mAb therapy frunevetmab for cats and a pivotal safety study o |
|
| November 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 4, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorpo |
|
| November 4, 2016 |
Nexvet Biopharma 10-Q (Quarterly Report) nvet-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001 |
|
| November 4, 2016 |
Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) Three Months Ended September 30, 2016 Three Months Ended September 30, 2015 Earnings: Net loss $ (5,095 ) $ (3,9600 ) Add: Fixed charges 16 61 Earnings as defined $ (5,079 ) $ (3,9544 ) Fixed charges: Estimated interest component of rental expense (1) $ 26 $ 61 Total fix |
|
| October 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| October 17, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| September 2, 2016 |
Nexvet Biopharma Reports Full Year Fiscal 2016 Results EX-99.1 Exhibit 99.1 Nexvet Biopharma Reports Full Year Fiscal 2016 Results DUBLIN, Ireland ? September 2, 2016 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapeutics company, today announced financial results for its 2016 fiscal year, which concluded on June 30, 2016. Corporate Highlights: ? Announced positive data from a multi-center, placebo-controlled, randomized, double-blind p |
|
| September 2, 2016 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| September 2, 2016 |
www.sec.gov/Archives/edgar/data/1618561/ 000156459016024880/nvet-10k_20160630.htm nvet-10k20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3682 |
|
| September 2, 2016 |
Exhibit 21.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) Three Months Ended June 30, 2016 Twelve Months Ended June 30, 2016 Earnings: Net loss $ (3,969 ) $ (19,3656 ) Add: Fixed charges 29 911 Earnings as defined $ (3,940 ) $ (19,2745 ) Fixed charges: Estimated interest component of rental expense (1) $ 29 $ 911 Total fixed ch |
|
| June 9, 2016 |
Monthly injectables for chronic dog and cat pain EX-99.1 Exhibit 99.1 Monthly injectables for chronic dog and cat pain Clinical data and discussion ACVIM Forum 2016 Welcome! Introductions and overview Agenda Dr. J?rgen Horn Dr. med.vet, PhD, MBA Overview Prof. Duncan Lascelles BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS Chronic pain?management & measurement (dogs and cats) Dr. Colin Giles BVetMed, PhD, MRCVS Ranevetmab ? clinical data |
|
| June 9, 2016 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| June 9, 2016 |
EX-99.2 Exhibit 99.2 Nexvet Presents Expanded Positive Clinical Data for Ranevetmab (NV-01) and Frunevetmab (NV-02) at ACVIM DUBLIN, Ireland - June 9, 2016 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapeutics company, is today presenting expanded results regarding completed clinical studies for ranevetmab (or ?NV-01?) and frunevetmab (or ?NV-02?) to veterinarians and veterinary ke |
|
| June 3, 2016 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 3, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporati |
|
| June 3, 2016 |
EX-99.1 Exhibit 99.1 Investor update 3 June 2016 Nexvet*TM Transforming animal medicine Forward-looking statements This presentation and other presentations given today contain forward-looking statements. All statements, other than statements of historical facts, contained in these slides and the accompanying oral presentation, including statements regarding our future results of operations and fi |
|
| May 26, 2016 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| May 26, 2016 |
EX-99.1 Exhibit 99.1 Nexvet Announces Positive Results from NV-02 Pilot Field Study in Cats with Osteoarthritis NV-02 Pivotal Study Plans Underway DUBLIN, Ireland - May 26, 2016 - Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapeutics company, today announced statistically significant efficacy results from its randomized, placebo-controlled pilot field study of NV-02, an anti-nerve gr |
|
| May 12, 2016 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| May 12, 2016 |
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2016 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2016 DUBLIN, Ireland ? May 12, 2016 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced its financial results for the three and nine-month periods ended March 31, 2016. Recent company highlights include: ? Advanced clinical development and regulatory preparations for ranevetmab ( |
|
| May 12, 2016 |
Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) Three Months Ended March 31, 2016 Nine Months Ended March 31, 2016 Earnings: Net loss $ (5,745 ) $ (15,396 ) Add: Fixed charges 26 61 Earnings as defined $ (5,719 ) $ (15,335 ) Fixed charges: Estimated interest component of rental expense (1) $ 26 $ 61 Total fixed charge |
|
| May 12, 2016 |
NVET / Nexvet Biopharma plc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36828 Nexvet Biopharma p |
|
| May 6, 2016 |
May 6, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-4561 Re: Nexvet Biopharma public limited company Amendment No. |
|
| May 3, 2016 |
S-3/A Table of Contents As filed with the Securities and Exchange Commission on May 3, 2016 Registration No. |
|
| May 3, 2016 |
DLA Piper LLP (US) 701 Fifth Avenue, Suite 7000 Seattle, Washington 98104-7044 www. |
|
| April 29, 2016 |
Mail Stop 4720 April 28, 2016 Mark Heffernan, Ph.D. Chief Executive Officer and Director Nexvet Biopharma plc Unit 5, Sragh Technology Park Rahan Road, Tullamore Co. Offaly, R35 FR98, Ireland Re: Nexvet Biopharma plc Registration Statement on Form S-3 Filed April 22, 2016 File No. 333-210876 Dear Dr. Heffernan: We have limited our review of your registration statement to those issues we have addre |
|
| April 22, 2016 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on April 22, 2016 Registration No. |
|
| April 22, 2016 |
EX-4.5 Exhibit 4.5 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY AND [?], AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF [?], 20[?] NEXVET BIOPHARMA PUBLIC LIMITED COMPANY FORM OF ORDINARY SHARE WARRANT AGREEMENT THIS ORDINARY SHARE WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between NEXVET BIOPHARMA PUBLIC LIMITED COMPANY, an Irish public limited company (the ?Company |
|
| April 22, 2016 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES AND PREFERENCE SHARE DIVIDENDS (in thousands) Three Months Ended December 31, Six Months Ended December 31, Year Ended June 30, 2015 2015 2015 2014 2013 Earnings: Net loss $ (5,691 ) $ (9,651 ) $ (11,857 ) $ (6,710 ) $ (3,241 ) Add: Fixed charges 23 35 60 30 7 Earnings as defined $ (5,714 ) $ (9,686 ) $ (11, |
|
| April 22, 2016 |
EX-4.3 Exhibit 4.3 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY, ISSUER AND [?], TRUSTEE INDENTURE DATED AS OF [?], 20[?] DEBT SECURITIES Table of Contents Page ARTICLE I DEFINITIONS 4 Section 1.1 Definitions of Terms 4 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 8 Section 2.1 Designation and Terms of Securities 8 Section 2.2 Form of Securities and Trustee?s |
|
| April 22, 2016 |
EX-4.6 Exhibit 4.6 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY AND [?], AS WARRANT AGENT FORM OF PREFERENCE SHARES WARRANT AGREEMENT DATED AS OF [?], 20[?] NEXVET BIOPHARMA PUBLIC LIMITED COMPANY FORM OF PREFERENCE SHARES WARRANT AGREEMENT THIS PREFERENCE SHARES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between NEXVET BIOPHARMA PUBLIC LIMITED COMPANY, an Irish public limited company (the |
|
| April 22, 2016 |
EX-4.7 Exhibit 4.7 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY AND [?], AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [?], 20[?] NEXVET BIOPHARMA PUBLIC LIMITED COMPANY FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between NEXVET BIOPHARMA PUBLIC LIMITED COMPANY, an Irish public limited company (the ?Compa |
|
| March 8, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incor |
|
| March 8, 2016 |
Exhibit 99.1 Exhibit 99.1 Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With Osteoarthritis Effectiveness Submission to the FDA-CVM on Track for 2Q 2016 DUBLIN, Ireland - March 8, 2016 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company?s anti-nerve g |
|
| February 16, 2016 |
NVET / Nexvet Biopharma plc / BioScience Managers PTY LTD - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nexvet Biopharma plc (Name of Issuer) Ordinary Shares, nominal value $0.125 per share (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 16, 2016 |
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2016 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2016 DUBLIN, Ireland ? February 16, 2016 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced its financial results for the three and six month periods ended December 31, 2015. Corporate highlights during the quarter: ? Announced successful results from pivotal safety and efficac |
|
| February 16, 2016 |
NVET / Nexvet Biopharma plc 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36828 Nexvet Biopharm |
|
| February 16, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2016 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporat |
|
| February 12, 2016 |
Nexvet Biopharma 3G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 d704269113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nexvet Biopharma plc (Name of Issuer) Ordinary Shares, $0.125 nominal value per share (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 12, 2016 |
NVET / Nexvet Biopharma plc / Foresite Capital Fund II, L.P. - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* NexVet Biopharma PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2015 (Date of Event Which Require |
|
| January 11, 2016 |
NVET / Nexvet Biopharma plc / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Nexvet Biopharma plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 28, 2015 |
NVET / Nexvet Biopharma plc / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 23, 2015 |
EX-99.1 To our Animal Health Symposium Welcome! 23 November 2015 NASDAQ: NVET Exhibit 99.1 The animal health industry and opportunities for innovation: Dr George Gunn An overview of Nexvet: Details of the successful NV-01 pivotal study Next steps for Nexvet?s development programs PETization and Nexvet?s R&D Finances and corporate structure Partnerships, market opportunities and near-term catalysts |
|
| November 23, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 23, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of I |
|
| November 20, 2015 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 20, 2015 Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| November 16, 2015 |
EX-99.1 Exhibit 99.1 Nexvet Announces Positive Results from NV-01 Pivotal Study in Dogs with Osteoarthritis Primary Endpoint Achieved Conference Call November 16th at 9:00AM ET DUBLIN, Ireland ? Nov. 16, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced positive results from its pivotal safety and efficacy study of NV-01, the Company?s anti-nerve growth fact |
|
| November 16, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 16, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of I |
|
| November 5, 2015 |
Nexvet Reports Financial Results for First Quarter of Fiscal Year 2016 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for First Quarter of Fiscal Year 2016 DUBLIN, Ireland ? November 5, 2015 ? Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three month period ended September 30, 2015. Corporate Highlights ? Commenced a research and development collaboration with leading Japanese animal health |
|
| November 5, 2015 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 5, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorpo |
|
| October 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| October 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| October 2, 2015 |
NEXVET BIOPHARMA PLC LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Damian Lismore and Geraldine Farrell, and each of them, as the undersigned's true and lawful attorney-in-fact (the "Attorney-in-Fact"), with full power of substitution and resubstitution, each with the power to act alone for the undersigned and in the undersigned's name, place and stead, in any and all capacities to: 1. |
|
| September 17, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 16, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of |
|
| September 17, 2015 |
Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support EX-99.1 Exhibit 99.1 Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support DUBLIN, Ireland - 16 September, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced it has secured a dedicated biologics manufacturing facility in Tullamore, Ireland. The transaction is supported by the Irish Government?s Department of Jobs, Enterprise & Innovation t |
|
| September 3, 2015 |
Nexvet Biopharma Reports Full Year Fiscal 2015 Results EX-99.1 Exhibit 99.1 Nexvet Biopharma Reports Full Year Fiscal 2015 Results DUBLIN, Ireland ? September 3, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced financial results for its 2015 fiscal year, which concluded on June 30th. ?During this past year we advanced our lead programs, bolstered the leadership team and transitioned to the public markets via a |
|
| September 3, 2015 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 3, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| July 2, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incor |
|
| July 2, 2015 |
EX-99.1 Exhibit 99.1 30 June 2015 Dear Dr Gunn As previously agreed to with Nexvet, my tenure on the Board comes to an end on 30 June 2015. I therefore tender my immediate resignation as a Director of Nexvet Ltd. As such I also step down from the company?s Audit and Risk Committee. I have thoroughly enjoyed my tenure on the Board, having also chaired the Audit and Risk Committee for a period and a |
|
| June 8, 2015 |
Nexvet Advances Manufacturing Strategy EX-99.1 Exhibit 99.1 Nexvet Advances Manufacturing Strategy Agreement signed with FUJIFILM Diosynth Biotechnologies Key appointment made in Ireland DUBLIN, Ireland and MELBOURNE, Australia, June 8, 2015 Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, announced today an update to its manufacturing strategy. Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth |
|
| June 8, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| June 5, 2015 |
NEXVET BIOPHARMA PLC LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Damian Lismore and Geraldine Farrell, and each of them, as the undersigned's true and lawful attorney-in-fact (the "Attorney-in-Fact"), with full power of substitution and resubstitution, each with the power to act alone for the undersigned and in the undersigned's name, place and stead, in any and all capacities to: 1. |
|
| June 4, 2015 |
EX-99.1 Exhibit 99.1 Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats with Degenerative Joint Disease DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-ner |
|
| June 4, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 4, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| May 11, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorp |
|
| May 11, 2015 |
Nexvet Appoints Dr. Jürgen Horn as Chief Product Development Officer EX-99.1 Exhibit 99.1 Nexvet Appoints Dr. J?rgen Horn as Chief Product Development Officer DUBLIN, Ireland and MELBOURNE, Australia, May 11, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. J?rgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role a |
|
| May 8, 2015 |
Nexvet Biopharma 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Incorporatio |
|
| May 8, 2015 |
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2015 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2015 DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 ? Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three and nine month periods ended March 31, 2015. Corporate Highlights ? In February 2015, we closed our initial public offering of 4.0 |
|
| April 16, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 15, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Inco |
|
| April 16, 2015 |
Nexvet Provides Update on NV-01 Program EX-99.1 Exhibit 99.1 Nexvet Provides Update on NV-01 Program DUBLIN, Ireland and MELBOURNE, Australia, April 15, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapy developer, announced today an update on its development program for NV-01, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with canine osteoarthritis. Following the resul |
|
| April 1, 2015 |
Nexvet Biopharma Appoints Dr. George Gunn as Chairman EX-99.1 Exhibit 99.1 Nexvet Biopharma Appoints Dr. George Gunn as Chairman DUBLIN, Ireland; MELBOURNE, Australia ? April 01, 2015 ? Veterinary biologic therapy developer Nexvet Biopharma (NASDAQ: NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March |
|
| April 1, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Inco |
|
| March 25, 2015 |
NEXVET BIOPHARMA PLC (Company) (Company No. 547923) Option terms of issue EX-99.1 Exhibit 99.1 NEXVET BIOPHARMA PLC (Company) (Company No. 547923) Option terms of issue 1. ENTITLEMENT 1.1 Entitlement Each option (Option(s)) entitles the holder of the Option(s) (Holder) to subscribe for 1 fully paid Ordinary Share in the capital of the Company (Ordinary Share), subject to adjustment under these terms. 1.2 No rights in share until issue The Holder has no right to, or inte |
|
| March 25, 2015 |
S-8 As filed with the Securities and Exchange Commission on March 25, 2015 Registration No. |
|
| March 13, 2015 |
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2015 EX-99.1 Exhibit 99.1 Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2015 DUBLIN, Ireland and MELBOURNE, Australia, March 13, 2015 ? Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2014. Corporate Highlights ? Commenced a pivotal safety and efficacy study for lead pr |
|
| March 13, 2015 |
Nexvet Biopharma FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other Jurisdiction of Inco |
|
| March 10, 2015 |
NVET / Nexvet Biopharma plc / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nexvet Biopharma plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) February 27, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| March 9, 2015 |
Nexvet Provides Update on Pivotal Field Safety and Efficacy Study for NV-01 EX-99.1 Exhibit 99.1 Nexvet Provides Update on Pivotal Field Safety and Efficacy Study for NV-01 DUBLIN, Ireland; MELBOURNE, Australia - March 9, 2015 ? Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapy developer, announced today an update on its pivotal field safety and efficacy study for its lead product candidate (NV-01), a novel monoclonal antibody (mAb) therapy for the control of |
|
| March 9, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d889510d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2015 Date of report (Date of earliest event reported) Nexvet Biopharma public limited company (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36828 98-1205017 (State or Other |
|
| February 20, 2015 |
NVET / Nexvet Biopharma plc / FARALLON CAPITAL MANAGEMENT LLC - 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEXVET BIOPHARMA PLC (Name of Issuer) Ordinary Shares, $0.0125 nominal value per share (Title of Class of Securities) G6503X109 (CUSIP Number) February 10, 2015 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| February 11, 2015 |
NVET / Nexvet Biopharma plc / Foresite Capital Fund II, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* NexVet Biopharma PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G6503X109 (CUSIP Number) February 5, 2015 (Date of Event Which Requires |
|
| February 6, 2015 |
NVET / Nexvet Biopharma plc CT ORDER - - begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C4Q(#`@;V)J#3P\+TQI;F5A08`X&B4F""&\0MP0D,0/$]06QM$`L3A#+#DB\OL7`Q,AP M",AB8&!$)XS+OT#$&``6'<)!@T*96YD8F!@X&9@8,IG``+AM0RH@!&(61@X&I#%N*&8@9&+@8M!98JM8U3'0QX% M^\,."3`].FLA-.N"X6!@;[F1!11E6```,`S(4)50T*96YD%LP+C`@,"XP(#8Q,BXP(#%LP M+C`@,"XP(#8Q,BXP(#3*>3K,E7 M1"?.^>[Q\I)>-\N\;`EG0M-I]O0I+]:;UN41]$/>F2X29NALFZT;DD@ZJ\IV M,JE^/5PH9=%&!&,,$SRB=9;MBNW+NT6QR |
|
| February 5, 2015 |
4,000,000 Shares Ordinary Shares 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-201309 P R O S P E C T U S 4,000,000 Shares Ordinary Shares Nexvet Biopharma public limited company is offering 4,000,000 ordinary shares. This is our initial public offering and, prior to this offering, there has been no public market for our ordinary shares. Our ordinary shares have been approved for listing on the Nas |
|
| February 2, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - Acceleration Request Letter for the Underwriter February 2, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 2, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - Acceleration Request Letter for the Company February 2, 2015 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| January 30, 2015 |
NVET / Nexvet Biopharma plc S-1/A - - AMENDMENT NO. 2 TO FORM S-1 Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2015 Registration No. 333-201309 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nexvet Biopharma public limited company (Exact name of registrant as specified in its charter) Ir |
|
| January 30, 2015 |
NVET / Nexvet Biopharma plc 8-A12B - - 8-A12B 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Nexvet Biopharma public limited company (Exact name of registrant as specified in its charter) Ireland 98-1205017 (State of incorporation or organization) (I.R.S. Employer Identification No. |
|
| January 30, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - CORRESP DLA Piper LLP (US) 1251 Avenue of the Americas, 27th Floor New York, New York 10020-1104 www. |
|
| January 26, 2015 |
EX-4.2 Exhibit 4.2 Shareholders agreement Relating to Nexvet Biopharma Limited Nexvet Biopharma Limited (Company) The parties specified in Schedule 9 (Shareholders) Shareholders agreement Details 6 Agreed terms 7 1. Defined terms & interpretation 7 1.1 Defined terms 7 1.2 Interpretation 14 1.3 Headings 14 1.4 New classes of Preference Shares 15 2. Not Used 15 3. Objectives 15 4. Board of Directors |
|
| January 26, 2015 |
INCORPORATED UNDER THE LAWS OF IRELAND EX-4.1 Exhibit 4.1 NUMBER NV INCORPORATED UNDER THE LAWS OF IRELAND Nexvet TM SHARES CUSIP G6503X 10 9 SEE REVERSE FOR CERTAIN DEFINITIONS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE ORDINARY SHARES, $0.125 NOMINAL VALUE, OF NEXVET BIOPHARMA PLC transferable on the books of the Company in person or by duly authorized attorney upon surrender of this Certificate properly |
|
| January 26, 2015 |
EX-1.1 Exhibit 1.1 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (an Irish public limited company) [—] Ordinary Shares UNDERWRITING AGREEMENT Dated: [—], 2015 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (an Irish public limited company) [—] Ordinary Shares UNDERWRITING AGREEMENT [—], 2015 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC as Representatives of the several Underwriters |
|
| January 26, 2015 |
EX-10.19 EXHIBIT 10.19 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 2015 EQUITY INCENTIVE PLAN 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 8 3.3 Administration with Respect to Insiders 9 3.4 Commi |
|
| January 26, 2015 |
EX-10.21 Exhibit 10.21 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY REGISTRATION RIGHTS AGREEMENT 22 January 2015 TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 5 2.4 Obligations of the Company 6 2.5 Furnish Information 8 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnification 9 2 |
|
| January 26, 2015 |
AMENDMENT No. 10 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.7 Exhibit 10.7 Confidential AMENDMENT No. 10 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage [***] Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 23rd day of December 2014 BETW |
|
| January 26, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - CORRESP DLA Piper LLP (US) 1251 Avenue of the Americas, 27th Floor New York, New York 10020-1104 www. |
|
| January 26, 2015 |
NVET / Nexvet Biopharma plc S-1/A - - AMENDMENT NO. 1 TO FORM S-1 Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on January 26, 2015 Registration No. 333-201309 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nexvet Biopharma public limited company (Exact name of registrant as specified in its charter) Ir |
|
| January 23, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - SEC Response Letter January 23, 2015 DLA Piper LLP (US) 1251 Avenue of the Americas, 27th Floor New York, New York 10020-1104 www. |
|
| January 22, 2015 |
NVET / Nexvet Biopharma plc CORRESP - - Cheap Stock Letter DLA Piper LLP (US) 701 Fifth Avenue, Suite 7000 Seattle, Washington 98104-7044 www. |
|
| January 13, 2015 |
January 13, 2015 Via E-mail Mark Heffernan, Ph.D. Chief Executive Officer Nexvet Biopharma public limited company National Institute for Bioprocessing Research and Training Fosters Avenue, Mount Merrion Blackrock, Co. Dublin, Ireland Re: Nexvet Biopharma public limited company Registration Statement on Form S-1 Filed December 30, 2014 File No. 333-201309 Dear Dr. Hefferman: We have reviewed your r |
|
| December 30, 2014 |
EX-10.18 EXHIBIT 10.18 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 2014 EQUITY INCENTIVE PLAN 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 8 3.3 Administration with Respect to Insiders 9 3.4 Commi |
|
| December 30, 2014 |
MASTER COLLABORATION, SUPPLY AND DISTRIBUTION AGREEMENT EX-10.12 Exhibit 10.12 MASTER COLLABORATION, SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN VIRBAC, a company organized under the law of FRANCE, with registered office at 1ère avenue 2065 M – L.I.D., 06516, Carros, France - registered under number 417 350 311 RCS at Grasse, France, acting for itself and its Affiliates, herein duly represented by Christian Karst, Member of the Executive Board, Hereinaft |
|
| December 30, 2014 |
EX-99.1 Exhibit 99.1 CONSENT OF RAJIV PATEL Pursuant to Rule 438 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby consents to being named in the registration statement on Form S-1 and in all subsequent amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing p |
|
| December 30, 2014 |
AMENDMENT No. 2 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.3 Exhibit 10.3 Confidential AMENDMENT No. 2 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 1B - *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 17th day of June 2013 BETWEE |
|
| December 30, 2014 |
EX-10.14 Exhibit 10.14 December 22, 2014 Mark Heffernan Re: Your employment by Nexvet US, Inc. Dear Mark: On behalf of Nexvet US, Inc. (the “Company”), a wholly-owned subsidiary of Nexvet Biopharma plc, a company organized in the Republic of Ireland (the “Parent Company”), I am pleased to confirm your employment with the Company upon the following terms and conditions commencing upon the date (the |
|
| December 30, 2014 |
SPECIFIC DISTRIBUTION AGREEMENT FOR NV-01 PRODUCT EX-10.13 Exhibit 10.13 SPECIFIC DISTRIBUTION AGREEMENT FOR NV-01 PRODUCT THIS SPECIFIC DISTRIBUTION AGREEMENT is made between: VIRBAC, a company organized under the law of FRANCE, with registered office at 1ère avenue 2065 M – L.I.D., 06516, Carros, France - registered under number 417 350 311 RCS at Grasse, France, acting for itself and its Affiliates, herein duly represented by Christian Karst, |
|
| December 30, 2014 |
NVET / Nexvet Biopharma plc S-1 - Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on December 30, 2014 Registration No. |
|
| December 30, 2014 |
EX-10.17 EXHIBIT 10.17 DATED 4 September 2014 NEXVET BIOPHARMA PLC (CO NO. 547923) (“COMPANY”) (ADOPTED BY THE BOARD ON 18 SEPTEMBER 2014) LONG TERM INCENTIVE PLAN RULES CONTENTS 1. INTRODUCTION 4 Name of Plan 4 Objects of Plan 4 Commencement of Plan 4 Advice 4 2. DEFINED TERMS & INTERPRETATION 4 Defined terms 4 Interpretation 8 Primary Instruments 9 Headings 9 3. OPERATION OF THE PLAN 9 Plan oper |
|
| December 30, 2014 |
NVET / Nexvet Biopharma plc CORRESP - - CORRESP DLA Piper LLP (US) 1251 Avenue of the Americas, 27th Floor New York, New York 10020-1104 www. |
|
| December 30, 2014 |
EX-4.2 Exhibit 4.2 Shareholders agreement Relating to Nexvet Biopharma Limited Nexvet Biopharma Limited (Company) The parties specified in Schedule 9 (Shareholders) Shareholders agreement Details 6 Agreed terms 7 1. Defined terms & interpretation 7 1.1 Defined terms 7 1.2 Interpretation 14 1.3 Headings 14 1.4 New classes of Preference Shares 15 2. Not Used 15 3. Objectives 15 4. Board of Directors |
|
| December 30, 2014 |
AMENDMENT No. 6 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.5 EXHIBIT 10.5 Confidential AMENDMENT No. 6 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 9 – *** Stage 10 – *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 4th day of Sep |
|
| December 30, 2014 |
EX-10.16 Exhibit 10.16 December 22, 2014 Damian Lismore Re: Your employment as Chief Financial Officer of Nexvet US, Inc. Dear Damian: On behalf of Nexvet US, Inc. (the “Company”), a wholly-owned subsidiary of Nexvet Biopharma plc, a company organized in the Republic of Ireland (the “Parent Company”), I am pleased to confirm your employment with the Company upon the following terms and conditions |
|
| December 30, 2014 |
NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue EX-4.3 Exhibit 4.3 NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue 1. DEFINITIONS Terms not defined in the warrant have the same meaning as given in the Shareholders Agreement relating to the Company (Shareholders Agreement). 2. ENTITLEMENT 2.1 Each warrant entitles the holder to subscribe for 1 fully paid Ordinary Share in the capital of the Company, subject to adju |
|
| December 30, 2014 |
EX-3.1 EXHIBIT 3.1 COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (Amended by Special Resolution on 17 November 2014) COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 1. The name of the Company is: Nexvet Biopharma pu |
|
| December 30, 2014 |
EX-16.1 Exhibit 16.1 September 5, 2014 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Change in Principal Auditor” in the Registration Statement Form S-1, confidentially submitted on September 5, 2014, of Nexvet Biopharma plc and a |
|
| December 30, 2014 |
AMENDMENT No. 8 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.6 Confidential EXHIBIT 10.6 AMENDMENT No. 8 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 7C *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 10th day of October 2014 BETWE |
|
| December 30, 2014 |
AMENDMENT No. 3 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.4 Exhibit 10.4 Confidential AMENDMENT No. 3 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 9 – *** Stage 10 – *** Stage 11 – *** Stage 12 – *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDM |
|
| December 30, 2014 |
EX-10.19 Exhibit 10.19 Deed of Indemnity, Insurance and Access (1) Nexvet Biopharma public limited company (2) [Director or Officer name] THIS DEED is made on [Date] BETWEEN: 1. Nexvet Biopharma public limited company, a company incorporated in Ireland (registered no. 547923), whose registered office is at 88 Harcourt Street, Dublin 2, Ireland (the “Company”); and 2. [Director or Officer name] of |
|
| December 30, 2014 |
EX-10.15 Exhibit 10.15 Employment agreement Nexvet Australia Pty Ltd ACN 141 909 131 and David Gearing Table of contents 1. Definitions and interpretation 4 1.1 Definitions 4 1.2 Interpretation 7 2. Position 7 3. Status of agreement 7 3.1 Replacement of Earlier Agreements 7 3.2 Commencement date and term 8 4. Duties and Obligations 8 4.1 Duties 8 4.2 Obligations 8 4.3 Other appointments 8 4.4 Conf |
|
| December 30, 2014 |
AGREEMENT LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.1 Exhibit 10.1 AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL THIS AGREEMENT is made the 21st day of December 2012 BETWEEN 1. LONZA SALES AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland (“Lonza”) and 2. NEXVET BIOPHARMA PTY LTD of 9 Meaden Street, Southbank 3006, Victoria, Australia, (“Customer”). WHEREAS: A. Customer is the proprietor of the antibody |
|
| December 30, 2014 |
AMENDMENT No. 1 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.2 Exhibit 10.2 Confidential AMENDMENT No. 1 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 8 - *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 13th day of May 2013 BETWEEN |
|
| December 30, 2014 |
EX-21.1 EXHIBIT 21.1 List of Subsidiaries of Nexvet Biopharma public limited company Subsidiary Jurisdiction of Incorporation or Organization Nexvet Australia Pty Ltd Australia NVIP Pty Ltd Australia Nexvet US, Inc. Delaware Nexvet Ireland Limited Ireland Tevxen Limited Ireland Nexvet UK Limited United Kingdom |
|
| December 30, 2014 |
EX-3.2 EXHIBIT 3.2 COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (As amended by Special Resolution dated 17 November 2014) 1. The name of the Company is Nexvet Biopharma public limited company (the “Company”). 2. The Company is to be a public limited company. 3. The objects of the Company are: (a) To purchase or |
|
| December 30, 2014 |
AMENDMENT No. 1 the AGREEMENT dated 16 December 2013 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.9 Exhibit 10.9 Confidential AMENDMENT No. 1 TO the AGREEMENT dated 16 December 2013 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD (NV02) Schedule 2 9 Stage 9 *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 17 day of June 2014 BE |
|
| December 30, 2014 |
AGREEMENT LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.8 Exhibit 10.8 CONFIDENTIAL AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL THIS AGREEMENT is made the 16th day of December 2013 BETWEEN 1. LONZA SALES AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland (“Lonza”) and 2. NEXVET BIOPHARMA PTY LTD of 9 Meaden Street, Southbank 3006, Victoria, Australia , (“Customer”). WHEREAS: A. Customer is the proprietor o |
|
| December 30, 2014 |
LICENCE AGREEMENT LONZA SALES AG. NEXVET BIOPHARMA PTY LTD EX-10.7 Exhibit 10.7 CONFIDENTIAL LICENCE AGREEMENT between LONZA SALES AG. and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL INDEX ARTICLE TITLE 1. Definitions 2. Supply of System and Know-How 3. Ownership of Property and Intellectual Property 4 Licences 5. Payments 6. Royalty Procedures 7. Liability and Warranties 8. Confidentiality 9. Intellectual Property Enforcement 10. Term and Termination 11. Assig |
|
| December 30, 2014 |
EX-10.11 Exhibit 10.11 CONFIDENTIAL GS KO LICENCE ROW LICENSE AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD 1 CONFIDENTIAL INDEX ARTICLE TITLE PAGE 1. DEFINITIONS 3 2. SUPPLY OF THE SYSTEM, CDACF VERSION 8 SYSTEM AND SYSTEM KNOW-HOW 7 3. OWNERSHIP OF PROPERTY AND INTELLECTUAL PROPERTY 8 4. LICENSES 8 5. PAYMENTS 9 6. ROYALTY PROCEDURES 12 7. LIABILITY AND WARRANTIES 13 8. CONFIDENT |
|
| December 30, 2014 |
AMENDMENT No. 2 the AGREEMENT dated 16 December 2013 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.10 EXHIBIT 10.10 Confidential AMENDMENT No. 2 TO the AGREEMENT dated 16 December 2013 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD (NV02) Schedule Stage 8 *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 10th day of October 2014 |
|
| December 5, 2014 |
December 4, 2014 Via E-mail Mark Heffernan, Ph.D. Chief Executive Officer Nexvet Biopharma plc National Institute for Bioprocessing Research and Training Fosters Avenue, Mount Merrion Blackrock, Co. Dublin, Ireland Re: Nexvet Biopharma plc Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted November 19, 2014 CIK No. 0001618561 Dear Dr. Hefferman: We have reviewed your amended dra |
|
| November 19, 2014 |
EXHIBIT 21.1 List of Subsidiaries of Nexvet Biopharma public limited company Subsidiary Jurisdiction of Incorporation or Organization Nexvet Australia Pty Ltd Australia NVIP Pty Ltd Australia Nexvet US, Inc. Delaware Nexvet Ireland Limited Ireland Tevxen Limited Ireland Nexvet UK Limited United Kingdom |
|
| November 19, 2014 |
NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue EX-4.3 5 filename5.htm Exhibit 4.3 NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue 1. DEFINITIONS Terms not defined in the warrant have the same meaning as given in the Shareholders Agreement relating to the Company (Shareholders Agreement). 2. ENTITLEMENT 2.1 Each warrant entitles the holder to subscribe for 1 fully paid Ordinary Share in the capital of the Company, |
|
| November 19, 2014 |
AMENDMENT No. 2 the AGREEMENT dated 16 December 2013 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.10 EXHIBIT 10.10 Confidential AMENDMENT No. 2 TO the AGREEMENT dated 16 December 2013 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD (NV02) Schedule Stage 8 *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 10th day of October 2014 |
|
| November 19, 2014 |
EX-3.2 EXHIBIT 3.2 COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (As amended by Special Resolution dated 17 November 2014) 1. The name of the Company is Nexvet Biopharma public limited company (the “Company”). 2. The Company is to be a public limited company. 3. The objects of the Company are: (a) To purchase or |
|
| November 19, 2014 |
EX-3.1 EXHIBIT 3.1 COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY (Amended by Special Resolution on 17 November 2014) COMPANIES ACTS, 1963 TO 2013 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 1. The name of the Company is: Nexvet Biopharma pu |
|
| November 19, 2014 |
EX-10.15 9 filename9.htm EXHIBIT 10.15 DATED 4 September 2014 NEXVET BIOPHARMA PLC (CO NO. 547923) (“COMPANY”) (ADOPTED BY THE BOARD ON 18 SEPTEMBER 2014) LONG TERM INCENTIVE PLAN RULES CONTENTS 1. INTRODUCTION 4 Name of Plan 4 Objects of Plan 4 Commencement of Plan 4 Advice 4 2. DEFINED TERMS & INTERPRETATION 4 Defined terms 4 Interpretation 8 Primary Instruments 9 Headings 9 3. OPERATION OF THE |
|
| November 19, 2014 |
AMENDMENT No. 6 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.5 6 filename6.htm EXHIBIT 10.5 Confidential AMENDMENT No. 6 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 9 – *** Stage 10 – *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made th |
|
| November 19, 2014 |
NVET / Nexvet Biopharma plc DRSLTR - - DRSLTR DLA Piper LLP (US) 1251 Avenue of the Americas, 27th Floor New York, New York 10020-1104 www. |
|
| November 19, 2014 |
EX-4.2 Exhibit 4.2 Shareholders agreement Relating to Nexvet Biopharma Limited Nexvet Biopharma Limited (Company) The parties specified in Schedule 9 (Shareholders) Shareholders agreement Details 6 Agreed terms 7 1. Defined terms & interpretation 7 1.1 Defined terms 7 1.2 Interpretation 14 1.3 Headings 14 1.4 New classes of Preference Shares 15 2. Not Used 15 3. Objectives 15 4. Board of Directors |
|
| November 19, 2014 |
EXHIBIT 10.16 NEXVET BIOPHARMA PUBLIC LIMITED COMPANY 2014 EQUITY INCENTIVE PLAN 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 8 3.3 Administration with Respect to Insiders 9 3.4 Committee Comp |
|
| November 19, 2014 |
AMENDMENT No. 8 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.6 Confidential EXHIBIT 10.6 AMENDMENT No. 8 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 7C *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 10th day of October 2014 BETWE |
|
| November 19, 2014 |
NVET / Nexvet Biopharma plc DRS/A - - DRS/A Table of Contents Confidential Draft No. 2 submitted to the Securities and Exchange Commission on November 19, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nexvet Biopharma public limited company (Exact name of registrant as specified in its charter) Ireland 2834 98-1205017 |
|
| October 2, 2014 |
October 1, 2014 Via E-mail Mark Heffernan, Ph.D. Chief Executive Officer Nexvet Biopharma plc National Institute for Bioprocessing Research and Training Fosters Avenue, Mount Merrion Blackrock, Co. Dublin, Ireland Re: Nexvet Biopharma plc Draft Registration Statement on Form S-1 Submitted September 5, 2014 CIK No. 0001618561 Dear Dr. Hefferman: We have reviewed your draft registration statement an |
|
| September 5, 2014 |
EX-16.1 Exhibit 16.1 September 5, 2014 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Change in Principal Auditor” in the Registration Statement Form S-1, confidentially submitted on September 5, 2014, of Nexvet Biopharma plc and a |
|
| September 5, 2014 |
AGREEMENT LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.6 Exhibit 10.6 CONFIDENTIAL AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL THIS AGREEMENT is made the 16th day of December 2013 BETWEEN 1. LONZA SALES AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland (Lonza) and 2. NEXVET BIOPHARMA PTY LTD of 9 Meaden Street, Southbank 3006, Victoria, Australia , (Customer). WHEREAS: A. Customer is the proprietor o |
|
| September 5, 2014 |
AGREEMENT LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.1 Exhibit 10.1 AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL THIS AGREEMENT is made the 21st day of December 2012 BETWEEN 1. LONZA SALES AG, of Muenchensteinerstrasse 38, Ch-4002 Basel, Switzerland (“Lonza”) and 2. NEXVET BIOPHARMA PTY LTD of 9 Meaden Street, Southbank 3006, Victoria, Australia, (“Customer”). WHEREAS: A. Customer is the proprietor of the antibody |
|
| September 5, 2014 |
NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue EX-4.3 Exhibit 4.3 NEXVET BIOPHARMA LIMITED (Company) (Company No. 547923) Warrant terms of issue 1. DEFINITIONS Terms not defined in the warrant have the same meaning as given in the Shareholders Agreement relating to the Company (Shareholders Agreement). 2. ENTITLEMENT 2.1 Each warrant entitles the holder to subscribe for 1 fully paid Ordinary Share in the capital of the Company, subject to adju |
|
| September 5, 2014 |
AMENDMENT No. 1 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.2 Exhibit 10.2 Confidential AMENDMENT No. 1 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 8 - *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 13th day of May 2013 BETWEEN |
|
| September 5, 2014 |
EX-4.2 Exhibit 4.2 Shareholders agreement Relating to Nexvet Biopharma Limited Nexvet Biopharma Limited (Company) The parties specified in Schedule 9 (Shareholders) Shareholders agreement Details 6 Agreed terms 7 1. Defined terms & interpretation 7 1.1 Defined terms 7 1.2 Interpretation 14 1.3 Headings 14 1.4 New classes of Preference Shares 15 2. Not Used 15 3. Objectives 15 4. Board of Directors |
|
| September 5, 2014 |
LICENCE AGREEMENT LONZA SALES AG. NEXVET BIOPHARMA PTY LTD EX-10.5 Exhibit 10.5 CONFIDENTIAL LICENCE AGREEMENT between LONZA SALES AG. and NEXVET BIOPHARMA PTY LTD CONFIDENTIAL INDEX ARTICLE TITLE PAGE 1. Definitions 2. Supply of System and Know-How 3. Ownership of Property and Intellectual Property 4 Licences 5. Payments 6. Royalty Procedures 7. Liability and Warranties 8. Confidentiality 9. Intellectual Property Enforcement 10. Term and Termination 11. |
|
| September 5, 2014 |
AMENDMENT No. 2 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.3 Exhibit 10.3 Confidential AMENDMENT No. 2 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 1B - *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 17th day of June 2013 BETWEE |
|
| September 5, 2014 |
EX-10.12 Exhibit 10.12 NEXVET BIOPHARMA LIMITED (CO NO. 547923) (COMPANY) LONG TERM INCENTIVE PLAN RULES CONTENTS 1. INTRODUCTION 4 Name of Plan 4 Objects of Plan 4 Commencement of Plan 4 Advice 4 2. DEFINED TERMS & INTERPRETATION 4 Defined terms 4 Interpretation 8 Primary Instruments 9 Headings 9 3. OPERATION OF THE PLAN 9 Plan operates in accordance with Rules 9 Rules binding 9 4. PRINCIPAL CO |
|
| September 5, 2014 |
AMENDMENT No. 3 the AGREEMENT dated 21 December 2012 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.4 Exhibit 10.4 Confidential AMENDMENT No. 3 TO the AGREEMENT dated 21 December 2012 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD Schedule 2 Stage 9 *** Stage 10 *** Stage 11 *** Stage 12 *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDM |
|
| September 5, 2014 |
EX-21.1 EXHIBIT 21.1 List of Subsidiaries of Nexvet Biopharma plc Subsidiary Jurisdiction of Incorporation or Organization Nexvet Biopharma, Inc. Delaware NVIP Pty Ltd Australia Nexvet UK Limited United Kingdom |
|
| September 5, 2014 |
NVET / Nexvet Biopharma plc DRS - - DRS Table of Contents As submitted confidentially to the Securities and Exchange Commission on September 5, 2014 Registration No. |
|
| September 5, 2014 |
EX-10.8 Exhibit 10.8 CONFIDENTIAL GS KO LICENCE ROW LICENSE AGREEMENT between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD 1 CONFIDENTIAL INDEX ARTICLE TITLE PAGE 1. DEFINITIONS 3 2. SUPPLY OF THE SYSTEM, CDACF VERSION 8 SYSTEM AND SYSTEM KNOW-HOW 7 3. OWNERSHIP OF PROPERTY AND INTELLECTUAL PROPERTY 8 4. LICENSES 8 5. PAYMENTS 9 6. ROYALTY PROCEDURES 12 7. LIABILITY AND WARRANTIES 13 8. CONFIDENTIA |
|
| September 5, 2014 |
AMENDMENT No. 1 the AGREEMENT dated 16 December 2013 LONZA SALES AG NEXVET BIOPHARMA PTY LTD EX-10.7 Exhibit 10.7 Confidential AMENDMENT No. 1 TO the AGREEMENT dated 16 December 2013 between LONZA SALES AG and NEXVET BIOPHARMA PTY LTD (NV02) Schedule 2 9 Stage 9 *** Schedule 3 Price and Payment *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Confidential THIS AMENDMENT is made the 17 day of June 2014 BE |
